 |
|
Methods for Discerning Disease-Modifying Effects in Alzheimer Disease Treatment Trials
Arch Neurol. 2000;57:312-314.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
TREATMENTS SUCH as cholinesterase inhibitors, vitamin E, and ginkgo biloba have been shown to have clear but small effect sizes on clinical measures of dementia in randomized controlled trials for Alzheimer disease (AD). For each of these treatments, plausible mechanistic arguments, such as antioxidant effects or alteration of amyloid protein processing, have been proposed as to how they may retard the progression of disease. However, let's face it: we can argue until our plaques become dense-cored and we still don't know whether the observed effects are purely symptomatic or in fact represent a change in a fundamental aspect of the progressive neuropathology of AD itself. As attractive as these mechanisms may be, the innate slow and variable rate of progression of untreated AD requires additional methods to demonstrate more than a symptomatic treatment effect.
There are several ways to demonstrate a disease-modifying effect of an AD treatment. Some researchers have . . . [Full Text of this Article]
RELATED ARTICLE
Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease: Power Calculations and Estimates of Sample Size to Detect Treatment Effects
Nick C. Fox, Simon Cousens, Rachael Scahill, Richard J. Harvey, and Martin N. Rossor
Arch Neurol. 2000;57(3):339-344.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Changes in premorbid brain volume predict Alzheimer's disease pathology
Silbert et al.
Neurology 2003;61:487-492.
ABSTRACT
| FULL TEXT
|
